Immunotherapy: A Breakthrough in Cancer Treatment
Immunotherapy is one of the most exciting breakthroughs in modern cancer treatment. Unlike chemotherapy or radiation, which directly target cancer cells, immunotherapy boosts the body’s immune system to recognize and destroy these cells. Over the past decade, this approach has transformed options for many patients with advanced or treatment-resistant cancers. While not everyone responds, overall success rates range from 20% to 50% across different cancer types and patient populations.
What Is Immunotherapy, and How Does It Work?
Immunotherapy is a type of treatment known as biological therapy, which combats cancer by using compounds from living things. Our immune system is composed of white blood cells, lymph nodes, antibodies, and lymphatic vessels. This is a body’s natural defense that acts against infections and unwanted cell growth. Cancer cells put up a disguise or use a cloak of invisibility to hide from the immune system, and immunotherapy removes that disguise or makes them visible again.
Immunotherapy’s primary mechanisms include:
- Checkpoint inhibition: Preventing cancer from using “off switches” to evade immune attack.
- Immune cell engineering (CAR-T): Modifying a patient’s T cells to hunt cancer cells.
- Cytokine therapy: The use of proteins to boost immune signaling and response.
- Cancer vaccines: educate the immune system to recognize specific tumor markers.
How Is Immunotherapy given?
The choice depends on the cancer type, stage, and patient-specific needs.
- Intravenous (IV): Administered through a vein for rapid distribution throughout the body.
- Oral: Pills or capsules taken at home for convenience.
- Intravesical: directly into the bladder for localized treatment, commonly in bladder cancer.
Immunotherapy Success Rates by Cancer Type
The overall response rate to immunotherapy varies greatly according to tumor biology and patient characteristics. Here is a summary based on clinical data:
| Cancer Type | Typical Response Rate | Notes |
| Melanoma | 40–50% | High because of the mutation load and immune visibility. |
| Non-Small Cell Lung Cancer (NSCLC) | 20–30% | Effective when checkpoint inhibitors like PD-L1 expression exceed 50%. |
| Kidney Cancer | ~25% | Checkpoint inhibitors frequently produce long-lasting responses. |
| Bladder Cancer | 20–25% | Strong response in PD-L1-positive cases. |
| Hodgkin’s Lymphoma | >60% | Highly susceptible to PD-1 inhibitors. |
| Head & Neck Cancers | 15–20% | Better outcomes for HPV-positive tumors. |
| Colorectal Cancer (MSI-High) | 40–50% | Only MSI-High or mismatch repair-deficient tumors respond favorably. |
A UCLA study discovered that treating lung cancer patients with pembrolizumab increased their five-year survival rate from 5.5% to 15%, nearly tripling the survival odds compared to traditional approaches.
Key Factors Affecting Immunotherapy Success
- Tumor Microenvironment: Certain cancers naturally activate stronger immune responses than others.
- Stage of Cancer: Typically used for advanced/metastatic cancers, but studies are looking into earlier use.
- Patient’s Overall Health: Stronger immune systems tend to respond better.
- Biomarker Presence
- PD-L1 Expression (higher levels may indicate a better response to certain immunotherapies)
- Tumor Mutational Burden (a high TMB indicates more mutations, potentially increasing immune recognition.)
- Microsatellite instability (MSI) (defective DNA repair, frequently linked to better immunotherapy outcomes)
Type of Immunotherapy
- Checkpoint inhibitors (such as pembrolizumab and nivolumab).
- CAR-T Cell Therapy
- Cytokine Therapy
Combination Therapies
Combining immunotherapy with chemotherapy, targeted drugs, or radiation often improves outcomes. - Genetic Profile
Certain mutations can change the immune system’s ability to detect cancer.
Advantages of Immunotherapy Over Traditional Treatments
- Even in advanced cases, it is possible to achieve long-term remission.
- Frequently produces fewer serious side effects than chemotherapy.
- Durable response means even after stopping treatment, some patients continue to respond.
Limitations and Challenges
- Not suitable for all patients or types of cancer.
- While many patients respond initially, only a small percentage (approximately 15-20%) see long-term benefits.
- Fatigue, autoimmune reactions, skin rashes, and inflammation are all potential side effects.
The future of immunotherapy
Future research aims to overcome current limitations through ongoing research that is improving immunotherapy’s targeting and efficacy. Some of the developments in immunotherapy include:
- Next-generation checkpoint inhibitors (advanced drugs that target new immune pathways to improve cancer control)
- Neoantigen vaccines (customized vaccines made from each patient’s tumor mutations to trigger an immune response)
- Oncolytic viruses (viruses designed to infect and kill cancer cells while also boosting immunity)
- Predicting treatment response using artificial intelligence (AI models that analyze patient data to predict therapy success).
Patient Eligibility, Cost, and Availability
Immunotherapy in India can cost between ₹2.5 lakh and ₹4 lakh per cycle, depending on the medication used. The majority of treatment options are available at major cancer centers in metropolitan areas. Eligibility is dependent on:
- Stage and type of cancer
- Status of biomarkers
- General well-being and organ performance
- Past medical history
- Insurance Coverage or Govt Schemes
Final Thoughts
Immunotherapy is revolutionizing the treatment of cancer. While the average success rate ranges between 20% and 50%, those who respond can reap significant, long-term benefits. Understanding the factors that influence success—from biomarkers to treatment combinations—allows doctors to better tailor therapies and maximize outcomes. With continued advancements and increased access, immunotherapy is poised to become a cornerstone of cancer treatment in the coming decade.
FAQs
What is the average success rate for immunotherapy in cancer?
Depending on the type of cancer, biomarkers, and stage, immunotherapy is effective in 20-50% of patients.
Which cancers respond well to immunotherapy?
Melanoma, Hodgkin’s lymphoma, MSI-High colorectal cancer, and certain lung and kidney cancers typically respond well.
Is it possible to completely cure cancer using immunotherapy?
In some cases, particularly melanoma and lymphoma, long-term remission has been achieved, but “cure” is uncommon and depends on a variety of factors.
How long does immunotherapy work after the treatment is stopped?
Some patients have long-term responses that last months or even years after treatment.
What are the side effects of immunotherapy?
Fatigue, rash, and inflammation are some of the most common side effects. Severe cases may include autoimmune reactions that affect organs.
How is immunotherapy different from chemotherapy?
Chemotherapy kills cancer cells but also harms healthy cells, whereas immunotherapy stimulates the immune system to target cancer more selectively.
Is immunotherapy available in India?
Yes, it is available at major cancer hospitals and specialized oncology centers, though the cost and availability may differ by location.
gdqoob